Madison-based Catalent has signed an agreement with Spicona, a New York company focused on research and development in the field of immunology and vaccinology, to develop a virus-like particle (VLP), protein-based vaccine against COVID-19.
According to a release from the company, Catalent will use its proprietary GPEx cell line technology to develop a cell line expressing the recombinant VLP.
